CG Oncology vs Roivant Sciences
Roivant Sciences reported revenue of $8 million in fiscal 2025, 2.1 times CG Oncology's $4 million in fiscal 2025. CG Oncology's revenue grew 254.7% in its latest year, and Roivant Sciences' fell 71.6%. CG Oncology had an operating margin of -4722.1%, against -6235.7% at Roivant Sciences. Free cash flow was −$132 million at CG Oncology and −$759 million at Roivant Sciences. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| CG Oncology | Roivant Sciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Mar 31, 2026 |
| Revenue | $4M | $8M |
| Revenue growth | 254.7% | −71.6% |
| Revenue growth a year, last 5 years | — | −19.0% |
| Gross margin | — | — |
| Operating margin | −4,722.1% | −6,235.7% |
| Net margin | −3,985.0% | −3,629.2% |
| Free cash flow | −$132M | −$759M |
| Free cash flow margin | −3,279.2% | −9,183.5% |
| Return on capital | — | −62.6% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.7% | −4.3% |
| Last close | $74.40 | $39.53 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $24.8 million, sold $4.8 million | sold $607.1 million |
| Piotroski F-score | 2 of 8 | 1 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CG OncologyRoivant Sciences
Operating margin
Percent of revenue
CG OncologyRoivant Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CG OncologyRoivant Sciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CG Oncology and Roivant Sciences pages.